Spyre Therapeutics reported two sets of data described as “two for two” for ulcerative colitis candidates SPY-001 and SPY-002, prompting analyst interest ahead of top-line readouts for the company’s anti-IL-23 antibody SPY-003. The updates reinforce expectations that Spyre’s modular inflammatory bowel disease approach may translate into differentiation across targets. The story highlights SPY-003 as the third biologic module in a six-candidate IBD lineup, suggesting a planned clinical progression that increasingly relies on comparative efficacy by mechanism. For drug developers watching IBD, the development matters because it pressures other IL-23 and inflammatory pathway programs to show clear clinical advantages rather than incremental safety-only narratives.